Insilico Medicine to present first-in-human data for AI-designed pan-TEAD inhibitor ISM6331 at ESMO 2026

Insilico Medicine strengthens its middle east presence with potential blood cancer treatment, generated by AI, first of its kind in the UAE

Genetic risk for PTSD may vary depending on the type of trauma experienced, data from more than 140,000 individuals suggests

Across four global innovation hubs: Insilico Medicine executive team to speak at premier healthcare and AI Summits